Global Acute Coronary Syndrome (ACS) Market 2015-2019
ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.
TechNavio's analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.
Covered in this Report
The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.
TechNavio's report, the Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
TechNavio Announces the Publication of its Research Report – Global ACS Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global ACS Market: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA
Other Prominent Vendors in the market are: AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals and Teva Pharmaceutical.
Commenting on the report, an analyst from TechNavio’s team said: “Growing public awareness of ACS is one of the key trends being witnessed in this market. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks.”
According to the report, the elderly population, from middle-aged and older, are more prone to developing ACS because with aging, plaque accumulates in the arteries, resulting in the narrowing of the arterial passage and difficulty in blood flow to the heart.
Further, the report states that patent expiry of a drug results in the loss of the exclusive market for that particular drug, thus leading to a rapid decline in its sales. Patent expiry of a drug results in the loss of the exclusive market, resulting in a rapid decline in the sales of that particular drug.
Astra Zeneca , BMS, Eli Lilly, GSK, Sanofi, AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo , Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals, Teva Pharmaceutical
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook